A phase II clinical trial testing electrochemotherapy on mucosal recurrent head and neck
cancer. Twenty-five patients will be treated. Primary outcome is tumour response on imaging.
Secondary outcomes are response from tissue samples, VAS score, Quality of life evaluation
and side effects to treatment.